These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20598596)

  • 1. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
    Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
    Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
    Queiroga FL; Pires I; Lobo L; Lopes CS
    Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
    Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
    Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
    Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD
    Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
    Gama A; Alves A; Schmitt F
    Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human and canine mammary tumors: a role for urokinase plasminogen activator?
    McGill LD
    Vet J; 2011 Jul; 189(1):1-2. PubMed ID: 21382730
    [No Abstract]   [Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
    Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
    Reilly D; Andreasen PA; Duffy MJ
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of regional lymph node status in canine mammary carcinomas.
    Szczubiał M; Łopuszynski W
    Vet Comp Oncol; 2011 Dec; 9(4):296-303. PubMed ID: 22077411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
    Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
    Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
    De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
    Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
    Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.